TMC125 (etravirine, ETR), Tibotec’s investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated significant efficacy in patients with NNRTI resistance, according to the 24-week primary endpoint analysis from two ongoing, phase III studies published in the 7 July, 2007, issue of The Lancet.
The studies, known as DUET-1 and DUET-2, examined the use of TMC125 in treatment-experienced HIV-1 patients with documented resistance to NNRTIs. TMC125 is the first NNRTI to show significant efficacy in patients with NNRTI resistance.
These data will be presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007), in Sydney, Australia, on 25th July, 2007.
“NNRTIs have been an important component of antiretroviral therapy for treatment-na?ve HIV patients for more than ten years, but the development of NNRTI resistance has limited their use beyond this population,” said Adriano Lazzarin, M.D., Vita-Salute, San Raffaele University, Milan, Italy. “The results from the DUET studies indicate an expanded role for this already well-understood and powerful class of antiretrovirals. The data suggest that TMC125 is the first sequenceable NNRTI for patients with resistance.”